Table 1 Collected data related to the use of antibiotics in COVID-19 (up to July 5, 2020)
From: Repurposing of antibiotics for clinical management of COVID-19: a narrative review
| Authors name + reference | Antibiotics | Types of study | Potential viral targets and/or other properties | IC50 inhibition or posology |
|---|---|---|---|---|
| Pani et al. [82] | Azithromycin | Review | Anti-inflammatory and immunomodulatory effects | Not indicated |
| Choudhary et al. [83] | Azithromycin | Review | Membrane fusion inhibition | Not indicated |
| Gautret et al. [26] | Azithromycin | Non-randomized clinical trial | Membrane fusion inhibition | 500 mg on the first day then 250 mg/day for 5 more days |
| Andreani et al. [32] | Azithromycin | In vitro | Membrane fusion inhibition | 10 and 5 μM |
| Touret et al. [84] | Azithromycin, levofloxacin | In vitro | Membrane fusion inhibition and replication inhibition | Not indicated |
| Ceccarelli et al. [42] | Teicoplanin | Letter to the editor | Interaction between viral spike protein and ACE2 receptors inhibition | 6 mg/kg every 24 h |
| Baron et al. [41] | Teicoplanin | Editorial | Interaction between viral spike protein and ACE2 receptors inhibition | Not indicated |
| Zhang et al. [43] | Teicoplanin | Original article | Interaction between viral spike protein and ACE2 receptors inhibition | 1.66 µΜ |
| Sathyamoorthy et al. [85] | Teicoplanin | Letter to the editor | Interaction between viral spike protein and ACE2 receptors inhibition | Not indicated |
| He and Garmire [86] | COL-3 (a chemically modified tetracycline) | Computational study | Interaction between viral spike protein and ACE2 receptors inhibition | Not indicated |
| Sodhi and Etminan [87] | Tetracyclines | Letter to the editor | Zinc‐chelating and anti-inflammatory effects | Not indicated |
| Wang [58] | Eravacycline, streptomycin | Computational study | Replication inhibition | Not indicated |
| Conforti et al. [88] | Doxycycline | Letter to the editor | Anti-inflammatory effect | Not indicated |
| Farouk and Salman [89] | Doxycycline | Letter to the editor | Anti-inflammatory effect | Not indicated |
| Malek et al. [90] | Doxycycline | Editorial | Anti-inflammatory effect | Not indicated |
| Szolnoky [91] | Doxycycline | Letter to the editor | Anti-inflammatory effect | Not indicated |
| Sargiacomo et al. [52] | Doxycycline, azithromycine | Research perspective | Protein synthesis, viral replication inhibition | Not indicated |
| Bonzano et al. [92] | Doxycycline | Opinion | Protein synthesis, viral replication inhibition, and immunomodulatory effect | Not indicated |
| Karampela and Dalamaga [64] | Levofloxacin, moxifloxacin | Opinion | Immunomodulatory effect | Not indicated |
| Marciniec et al. [65] | Ciprofloxacin, moxifloxacin | In silico study | Viral replication inhibition | Not indicated |
| Durojaiye et al. [81] | Cefuroxime | In silico study | Interaction between viral spike protein and ACE2 receptors and viral replication inhibition | Not indicated |
| Chalichem et al. [73] | Aminoglycosides | Membrane fusion inhibition | Not indicated |